Bioventus Inc.

Bioventus Inc. announced that the FDA reclassified non-invasive bone growth stimulators, including its Exogen® Ultrasound Bone Healing System, from Class III to Class II devices. Following this, CMS updated billing requirements and the Medicare fee schedule for related HCPCS codes, effective May 18, 2026. The company currently does not expect these changes to materially impact its financial results for fiscal year 2026 and is reiterating its previously issued guidance. However, Bioventus will continue to evaluate potential long-term impacts of current and future CMS actions.

Bioventus Inc. reported strong financial results for the first quarter ended March 28, 2026, with net sales increasing by 6.6% to $132.1 million and a significant turnaround to net income of $3.9 million, compared to a net loss in the prior year. The company also made a discretionary prepayment of $22.0 million on its 2025 Term Loan, demonstrating improved financial management. These results follow the divestiture of its Advanced Rehabilitation Business in late 2024, allowing for a focus on core operations.

Bioventus Inc. reported strong first-quarter 2026 financial results, with revenue increasing 7% to $132.1 million. The company achieved GAAP earnings of $0.04 per diluted share, a significant improvement from a loss in the prior year, and non-GAAP earnings of $0.15 per diluted share. Driven by accelerated cash flow and debt repayment, Bioventus raised its full-year 2026 guidance for Adjusted EPS and Cash from Operations, while reaffirming its net sales outlook.

Bioventus reported a strong Q1 2026 with revenue increasing 7% to $132.1 million, driven by growth across all business segments. GAAP earnings improved significantly to $0.04 per diluted share from a prior-year loss, and non-GAAP earnings rose 88% to $0.15 per diluted share. The company also generated $8.9 million in cash from operations, a substantial increase from a prior-year outflow. Consequently, Bioventus raised its full-year 2026 non-GAAP EPS and Cash from Operations guidance, while reaffirming its revenue outlook.

Bioventus Inc. announced it will release its first quarter fiscal year 2026 financial results before the market opens on Wednesday, May 6, 2026. Following the release, the company's management will host a conference call at 8:30 a.m. Eastern Time to discuss the results and provide a business update. A live webcast of the call will also be available on the company's investor relations website.